NASDAQ: LIANLianbio Stock
$2.52+0.05 (+2.02%)
Updated Jun 8, 2023
LIAN Price
$2.52
Fair Value Price
N/A
Market Cap
$270.05M
52 Week Low
$1.07
52 Week High
$3.25
P/E
-2.57x
P/B
1.12x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
$0.00
Earnings
-$106.61M
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.12
Operating Cash Flow
-$104M
Beta
1.73
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
LIAN Overview
LianBio, a biopharmaceutical company, is developing medicines for cardiovascular, oncology, respiratory, opthalmology, and inflammatory diseases in China and other Asian countries. It is developing "mavacamten" for the treatment of obstructive and non-obstructive hypertrophic cardiomyopathy and heart failure with preserved ejection fraction, TP-03 for the treatment of Demodex blepharitis, and NBTXR3 for the treatment of head and neck squamous cell carcinoma and solid tumors, Infigratinib for the treatment of second-line and first-line cholangiocarcinoma and gastric cancers. LianBio was incorporated in 2019 and is headquartered in Princeton, NJ.
Zen Score
–
Industry Average (26)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how LIAN scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
LIAN is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
LIAN is good value based on its book value relative to its share price (1.12x), compared to the US Biotechnology industry average (5.24x)
P/B vs Industry Valuation
LIAN is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more LIAN due diligence checks available for Premium users.
Be the first to know about important LIAN news, forecast changes, insider trades & much more!
LIAN News
Valuation
LIAN price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-2.57x
Industry
11.75x
Market
52.58x
LIAN price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.12x
Industry
5.24x
LIAN is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
LIAN's financial health
Profit margin
Revenue
$0.0
Net Income
-$24.0M
Profit Margin
0%
LIAN's cash and short-term investments... subscribe to Premium to read more.
Interest Coverage Financials
Assets to liabilities
Assets
$302.6M
Liabilities
$28.2M
Debt to equity
0.12
LIAN's short-term assets ($296.05M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
LIAN's short-term assets ($296.05M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
LIAN's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$17.6M
Investing
$40.5M
Financing
$0.0
LIAN's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
LIAN vs Biotech Stocks
Lianbio Stock FAQ
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.